Review Article

Interleukin-19 in Breast Cancer

Ying-Yin Chen,1,2,3 Chien-Feng Li,4 Ching-Hua Yeh,5 Ming-Shi Chang,6 and Chung-Hsi Hsing1,2,7

1 Department of Medical Research, Chi-Mei Medical Center, Tainan 710, Taiwan
2 Department of Anesthesiology, Chi-Mei Medical Center, Tainan 710, Taiwan
3 Department of Biotechnology, National Formosa University, Yunlin 632, Taiwan
4 Department of Pathology, Chi-Mei Medical Center, Tainan 710, Taiwan
5 Institute of Medical Science, College of Health Science, Chang Jung Christian University, Tainan 711, Taiwan
6 Institute of Biochemistry and Molecular Biology, Medical College, National Cheng Kung University, Tainan 701, Taiwan
7 Department of Anesthesiology, College of Medicine, Taipei Medical University, Taipei 110, Taiwan

Correspondence should be addressed to Chung-Hsi Hsing; hsing@seed.net.tw

Received 13 January 2013; Revised 22 March 2013; Accepted 29 March 2013

Academic Editor: Nima Rezaei

Copyright © 2013 Ying-Yin Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Inflammatory cytokines within the tumor microenvironment are linked to progression in breast cancer. Interleukin-19 (IL-19), part of the IL-10 family, contributes to a range of diseases and disorders, such as asthma, endotoxic shock, uremia, psoriasis, and rheumatoid arthritis. IL-19 is expressed in several types of tumor cells, especially in squamous cell carcinoma of the skin, tongue, esophagus, and lung and invasive duct carcinoma of the breast. In breast cancer, IL-19 expression is correlated with increased mitotic figures, advanced tumor stage, higher metastasis, and poor survival. The mechanisms of IL-19 in breast cancer have recently been explored both in vitro and in vivo. IL-19 has an autocrine effect in breast cancer cells. It directly promotes proliferation and migration and indirectly provides a microenvironment for tumor progression, which suggests that IL-19 is a prognostic marker in breast cancer and that antagonizing IL-19 may have therapeutic potential.

1. Introduction

Breast cancer is one of the most common malignant tumors in women [1] and becoming the principal cause of cancer death. The etiology of breast cancer is multifactorial, and its clinical course and molecular and pathological features are highly diverse [2]. Estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER2) are recognized as common clinical tumor markers for tumor growth and progression and as indicators of determining appropriate therapy for patients with breast cancer [3]. A lack of these factors has consistently been associated with a poorer prognosis [4]. In addition to these three molecular markers, a growing body of evidence has associated inflammation with a poor prognosis and reduced survival in patients with breast cancer [5, 6]. Cytokines, one of the inflammatory mediators, are emerging as factors that may significantly affect the growth of tumors in vivo [7–10] and be important in breast carcinogenesis [7, 11–13]. The role of hematopoietic growth factors, interferons, lymphokines, chemokines, and cytokines in tumor microenvironments has been intensively studied [14–16], especially in breast cancer [7, 13, 17–19]. Cytokines have been implicated in the mechanism for tumor cell evasion of the immune surveillance system [20, 21].

Cytokines, which are low molecular weight pleiotropic glycoproteins, are secreted primarily by immune cells and affect many different adjacent target cells: they alter target-cell function and modulate cell death, growth, and differentiation at very low concentrations [2]. Cytokines produced by cancer tissue [11, 12] and the expression of interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12, and IL-19, monocyte-chemoattractant-protein (MCP-) 1, and macrophage-inflammatory-protein (MIP-) 1β are upregulated in breast cancer [7, 13, 17, 19]. Cytokines are important intercellular mediators of angiogenesis and leukocyte infiltration in breast cancer, and they promote or inhibit the growth of breast cancer depending
on their relative concentrations and the presence of other regulatory factors in the tumor microenvironment [2, 7]. Changes in the relative concentration of some cytokines, such as IL-1, IL-6, IL-11, and IL-19, and transforming-growth-factor- (TGF-) β, mediated both directly and indirectly by the tumor stimulate breast cancer proliferation and invasion [1, 7, 13]. Despite massive investment in biomarker discovery, only a few have been recognized as potential biomarkers and tested in clinical practice [7]. The need for robust and accurate diagnostic markers that predict responses to breast cancer therapy is urgent. We recently reported [13] that upregulated IL-19 in breast cancer promoted tumor progression and affected clinical outcome: increased IL-19 expression in invasive ductal carcinoma (IDC), human breast tissue was associated with tumor staging. Elevated IL-19 levels were also closely correlated with inflammatory cell components, which accounted for tumor progression and metastasis.

In this review, we focus on the crucial roles of IL-19 in breast carcinogenesis and highlight principal recent findings on the effects of IL-19 in clinical outcomes and mechanisms of tumorigenesis and metastasis. Additionally, the potential role of IL-19 for assessing tumor staging, tumor aggressiveness, and disease progression is discussed.

## 2. IL-19, a Recently Discovered IL-10 Family Cytokine, Modulates Inflammatory Diseases

IL-19 is found within the IL-10 family gene cluster: IL-10, -19, -20, -22, -24 (MDA-7), -26 (AK155), -28, and -29 [23–28]. An α-helical protein, IL-19 functions as a monomer and is structurally similar to IL-10, which contains a hydrophobic core held by two disulphide bonds formed by four specific positions of cysteine (Cys57–Cys109 and Cys58–Cys111) [29, 30]. Despite a sequence homology of up to 30% between 159 of their amino acids, the biological functions of IL-19 and IL-10 are distinct [27, 31–34]. Stimulating monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF), lipopolysaccharide (LPS), and other cytokines...
Figure 2: IL-19 overexpression promoted breast cancer cell proliferation and migration in vitro and induced tumor growth and metastasis in vivo. We constructed the IL-19-overexpressing stable clones of 67NR (67NR/IL-19) cells. (a) Proliferation of 67NR/IL-19 cells was significantly higher than that of control cells. Data are mean ± SEM of triplicate experiments. *P < 0.05 versus control-vector cells. (b) Cell migration, determined using a wound healing assay, was greater in 67NR/IL-19 cells than in control-vector cells. Quantitative results are shown as a wound healing index. Data are mean ± SEM. *P < 0.05 versus control-vector cells. (c) 67NR cells (2 × 10^6) were injected into the left mammary fat pads of BALB/c mice and tumor growth was determined. (d) Fifteen days later, the tumors were removed. Thirty days after the tumors had been surgically removed, the mice were killed, and histological analysis showed that lung metastasis (arrows) was significantly higher in 67NR/IL-19 cells than in control cells (magnification, ×100). Data are mean ± SEM (n = 6 mice in each group). *P < 0.05 versus control mice. The figure refers to Hsing et al. [13].

(IL-4, IL-6, IL-17, and TNF-α) induces them to express IL-19 [35, 36]. IL-19 spurs the production of IL-6 and TNF-α by monocytes [37] and the release of Th2 cytokines by T cells [38], signals through the IL-20R1/IL-20R2 heterodimeric receptor, which it shares with IL-20 and IL-24, but with a different binding affinity [39], and stimulates tyrosine phosphorylation and nuclear translocation of STAT3 [28, 40, 41]. IL-19 derived primarily from macrophages and, to a lesser extent, from B cells and nonimmune cells including epithelial cells, endothelial cells, skin keratinocytes, and fetal membranes [25, 42]. Many reports showed that IL-19 has proinflammatory effects [24, 27, 28, 37]. In contrast, IL-19 has an anti-inflammatory property identified in inflammatory bowel disease [43] and vascular inflammatory diseases [44]; this property directly induces hyporesponsiveness in CD4-positive (+) T cells and promotes their regulatory activity, which may contribute to immunosuppression in patients after cardiac surgery [45].
IL-19 contributes to a range of diseases and disorders, such as breast cancer [13], asthma [37], endotoxic shock [46], uremia [47], psoriasis [48], rheumatoid arthritis [49], and periodontal and vascular disease [24]. IL-19 expression in uremic patients is upregulated and correlated with Th2 immune responses that might be involved in cytokine dysregulation [47]. Induction of IL-19 occurs in severe sepsis [46] and postcardiopulmonary bypass patients with a parallel shift that corresponds to the changes in TNF-α and IL-6 [36]. Thus, the potentiation of IL-19 expression is recognized as important in the pathogenesis of systemic inflammatory diseases. In mice with endotoxic shock, IL-19 mRNA levels are elevated in brain, heart, lung, liver, and kidney tissues [46]. Upregulated IL-19 in sepsis induces lung and liver tissue injury by inducing apoptosis and the production of IL-6, IL-8, TNF-α, and reactive oxygen species (ROS) [46]. However, the effects of IL-19 on inflammatory bowel disease are therapeutic and significantly reduced innate-mediated colonic inflammation in murine model [43]. Its anti-inflammatory activity is also found in vascular inflammatory diseases: IL-19 attenuates the response to injury of vascular smooth muscle cells (VSMCs) by diminishing human antigen R-mediated proliferative and inflammatory mRNA transcripts [44] and promoting heme oxygenase-1-mediated ROS reduction [50]. Thus, IL-19 is a pleiotropic cytokine that can suppress or stimulate immune regulation and disease [24].

### 3. Cytokine IL-19 Is a Prognostic Marker in Breast Cancer

#### 3.1. IL-19 Is Involved in Tumor Biology

IL-19 expression in tumor cells has been investigated using tissue microarray technology and an immunohistochemical survey with an anti-IL-19 monoclonal antibody in 15 neoplastic tissue types (Table 1) [22]. IL-19 protein was positively stained in several types of tumor cells, especially in squamous cell carcinoma (SCC) of the skin, tongue, esophagus, and lung and invasive duct carcinoma (IDC) of the breast [22]. SCC of the oral cavity also expressed IL-19 mRNA and its receptors (IL-20R1/R2). In addition, IL-19 specifically activated intracellular signals and induced proliferation in two cell lines (OEC-M1 and OC3) derived from SCC of the oral cavity. This study provides important references for further investigation of the biological functions and clinical implications of IL-19 in humans.

#### 3.2. IL-19 Expression Is Correlated with Advanced Tumor Stage, Higher Metastasis, and Poor Survival

The most common form of breast cancer, IDC, begins in the cells that grow and form the ducts, and then it invades the fatty tissue outside of the duct and appears as a smooth-edged and hard tumor in the breast [7]. IL-19 expression was substantially greater in breast IDC tissue (Figure 1(a)A) than in healthy tissue (Figure 1(a)B) [13, 22]. IL-19 levels have been verified to be associated with primary tumor status (Table 2), advanced tumor stage, a high degree of occurrence of lymph node and distant metastasis, HER2 status, and the presence of mitotic figures (Figure 1(b)). Higher IL-19 expression levels predicted worse disease-specific survival (Figure 1(c)) and metastasis-free survival with more than 3-fold increased risk (HR = 3.322) (Table 3). However, the serum levels of IL-19 are unchanged with the tumor stage, which suggests that IL-19 levels in the local microenvironment are dominant rather than the systemic effect in breast cancer [13]. Thus, IL-19 expression in tumor cells is hypothesized to be involved in tumor progression and to correlate with the clinical outcome of breast cancer. Thus, IL-19 has the potential to be a prognostic marker for patients with an IDC breast tumor.

### 4. Mechanisms of IL-19 in Breast Cancer

#### 4.1. IL-19 Induced Proliferation, Migration, and Fibronectin Expression and Assembly in Breast Cancer Cells, and It Promoted Metastasis

IL-19 acts in breast tumors in an autocrine manner and the expression and colocalization of IL-19 and its cognate receptors can be seen both in human (MCF-7 and HS578T) and in mouse (67NR and 4T1) breast cancer cell lines [13]. In vitro assays showed that the mechanism of IL-19 in 4T1 cells is activating the intracellular signals STAT3, JNK, ERK, AKT, and NF-κb, which may be involved in cell proliferation and survival, but phosphorylation occurred only on JNK, ERK, and AKT in HS578T human breast cancer cells [13]. Fibronectin (FN) expression and assembly in tumor cells are well-known promoters of tumor progression and pulmonary metastasis in breast cancer [51]. IL-19 treatment promotes specific proliferation and migration activities as well as fibronectin expression and assembly both in human and in mouse breast cancer cells [13]. In MCF-7 cells, IL-19 directly promotes proliferation, which leads to the increase in the duration of the G2/M stage of the cell.
Table 2: Associations between IL-19 expression in 143 breast invasive duct carcinoma tumors with other important clinicopathologic variables.

| Parameters          | Category | n  | IL-19-L<sup>1</sup> (n = 68) | IL-19-H<sup>2</sup> (n = 75) | P       |
|---------------------|----------|----|-------------------------------|-------------------------------|---------|
| Age (years)         | <60      | 103| 54                           | 49                           | 0.061   |
|                     | ≥60      | 40 | 14                           | 26                           |         |
| Primary tumor (T)   | T1       | 50 | 33                           | 17                           | 0.003   |
|                     | T2       | 78 | 32                           | 46                           |         |
|                     | T3       | 10 | 3                            | 7                            |         |
|                     | T4       | 5  | 0                            | 5                            |         |
| Nodal status (N)    | N0       | 71 | 42                           | 29                           |         |
|                     | N1       | 56 | 25                           | 31                           | 0.001   |
|                     | N2       | 16 | 1                            | 15                           |         |
| Stage               | I        | 34 | 24                           | 10                           |         |
|                     | II       | 87 | 41                           | 46                           |         |
|                     | III      | 22 | 3                            | 19                           |         |
| HER2 expression     | Low (0+ to 2+) | 103  | 56                           | 47                           | 0.009* |
|                     | High (3+) | 40  | 12                           | 28                           |         |

<sup>1</sup>IL-19-L: low grade immunostaining, H score <200.
<sup>2</sup>IL-19-H: high grade immunostaining, H score ≥200.
<sup>3</sup>HER scoring was done using standard HercepTest guidelines.
* Statistically significant.

The table refers to Hsing et al. [13].

Table 3: Multivariate survival analyses for MFS.

| Parameter          | Category | MFS | HR      | 95% CI     | P        |
|--------------------|----------|-----|---------|------------|----------|
| IL-19 expression   | Low (H < 200) | 1   | —       | 0.0004*    |          |
|                    | High (H ≥ 200) | 3.322 | 1.711–6.453 |          |          |
| Stage              | I        | 1   | —       | 0.0079*    |          |
|                    | II-III   | 4.961 | 1.522–16.178  |          |          |

MFS: metastasis free survival.
HR: hazard ratio.
* Statistically significant.
The table refers to Hsing et al. [13].

cells [13]. A functional hypoxic response element has been found on IL-19 promoter, and hypoxia induces IL-19 expression consistent with the increased expression of CXCR4 in breast cancer cell lines [13]. In response to chemical (CoCl<sub>2</sub>) and physical (hypoxia chamber) hypoxia treatment, anti-IL-19 mAb attenuates hypoxia-induced CXCR4 expression <em>in vitro</em> [13]. Therefore, IL-19 may be an upstream molecule that mediates hypoxia-induced CXCR4 expression and metastasis. HER2 increases breast tumor metastasis by promoting the expression and preventing the ligand-induced degradation of CXCR4 [54]. We previously reported a significant clinical correlation between IL-19 and HER2 expression [13]. It would be interesting to explore the relationship between HER2 expression and the hypoxia/IL-19/CXCR4 pathway in the progression of breast cancer.

4.3. IL-19 and Extracellular Matrix and Cytokines Network in Breast Cancer. A variety of direct cell-cell, cell-matrix, and paracrine interactions and the release of cytokines are involved in metastasis [55]. With the assistance of polymeric FN assembly [51], breast cancer cells frequently invade other areas of the body, this metastasis is expected to be attenuated when FN-mediated endothelial adhesion is inhibited [56]. The effect of IL-19 on FN expression and assembly in breast cancer cells has been investigated [13]. FN expression was higher in MCF-7 cells, 4T1 cells, and Hs578T cells after IL-19 treatment. Knockdown of endogenous IL-19 in tumor cells inhibited FN expression and assembly, but overexpression of IL-19 induced FN production.

Cytokines may be involved in a network with a large variety of different members that facilitate tumor growth. Matrix metalloproteinase-2 (MMP-2) and IL-6 participate...
in endothelial cell injury and the extravasation of tumor cells [55], and IL-1β, IL-6, and TGF-β are involved in tumor progression [7]. In breast cancer, receptor gp130 mediates IL-6 signals; inhibiting IL-6 signaling and production in turn inhibits in vitro activation of STAT3 as well as in vivo tumor cell proliferation and number of metastases [7]. IL-19 induces IL-1β, IL-6, TGF-β, and MMP-2 in breast cancer cells. Because stimulation with IL-6 induces IL-19 expression, there may be positive feedback between IL-6 and IL-19 that elicits the STAT3 signal and the progression of breast cancer. It further supports that IL-19 not only directly facilitates cell proliferation, cell migration, and metastasis but it also prompts the expression of IL-1β, IL-6, TGF-β, MMP-2, MMP9, CXCR4, and fibronectin, which supply of a microenvironment for tumor growth and metastasis [13].

4.4. IL-19, Th2 Cytokines, and Tumor-Associated Macrophages. Th2 cytokines—IL-4, IL-13, and IL-10—induce alternatively activated macrophages by increasing macrophage mannose receptor activity [57]. Macrophage infiltration into premalignant mammary tissue was identified during mammary cancer progression in an animal model [58]. Cytokines expressed by Th2 cells regulate the chemoattraction and polarization of tumor-associated macrophages (TAMs) [1]. TAMs have poor antigen-presenting capacity and suppress T-cell activation and proliferation by releasing IL-10, TGF-β, and prostaglandins [8, 59]. Th2 cytokines promote M2-polarized phenotype TAMs and are pivotal in subverting adaptive immunity as well as in inflammatory circuits that promote tumor growth and progression [9, 60, 61]. In breast carcinomas, a high level of infiltrating TAMs is associated with a poor prognosis [62].

IL-19 shifts the balance of Th1 and Th2 cells toward Th2 dominance [63–65]. It stimulates secretion of Th2 cytokines (IL-4, -5, -10, and -13) and dose dependently attenuates the secretion of Th1 cytokine (IFN-γ) [38, 63]. IL-17 treatment induces IL-19 expression, and the IL-13 and -19 levels are closely correlated with the Th2 response in human asthma [24]. Treating LPS-stimulated monocytes with IL-4 or IL-13 potentiates IL-19 expression [35]. There may be positive feedback between IL-19 and Th2 cytokines. That Th2 cytokines induce the bioactivities of TAMs has been confirmed; however, the association between IL-19 and Th2-polarized TAMs remains to be clarified.

5. Conclusions

Breast cancer development and progression are known to be affected by the dynamic interplay between microenvironmental effectors and the immune responses and intrinsic properties of the tumor cells. Accumulated clinical and experimental data indicate that IL-19 is an important mediator in breast cancer. The consequences of IL-19 expression in breast cancer development and progression are as follows: (a) it affects the clinical outcome of breast cancer and tumor metastasis; (b) it increases cell proliferation, cell migration, and fibronectin assembly; (c) hypoxia induces IL-19-mediated gene-expression in cancer cells, which promotes proliferation (IL-1β, IL-6, and TGF-β), migration or metastasis (MMP2, MMP9, CXCR4, and fibronectin), or angiogenesis (MMP2 and MMP9); (d) it facilitates tumor growth and lung metastasis. Figure 3 shows a hypothetical working model related to the pathogenesis of tumor growth in breast cancer to explain the role of IL-19 in the pathogenesis of tumor progression. We conclude that IL-19 has an autocrine effect on breast cancer cells and provides a microenvironment for tumor progression. Antagonizing IL-19 might have therapeutic potential in breast cancer.

Conflict of Interests

The authors declare that they have no conflict of interests.
Acknowledgments

This work was supported by Grant CMFHR10151 from Chi-Mei Medical Center, Tainan, Taiwan, and by Grant NSC 101-2314-B-384-003-MY3 from the Taiwan National Science Council.

References

[1] D. G. DeNardo and L. M. Coussens, “Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression,” Breast Cancer Research, vol. 9, no. 4, p. 212, 2007.

[2] V. S. Rao, C. E. Dyer, J. K. Jameel, P. J. Drew, and I. Greenman, “Potential prognostic and therapeutic roles for cytokines in breast cancer (Review),” Oncology Reports, vol. 15, no. 1, pp. 179–185, 2006.

[3] L. S. Lindstrom, E. Karlsson, U. M. Wilking et al., “Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2601–2608, 2012.

[4] K. Yao-Lung, C. Dar-Ren, and C. Tsai-Wang, “Clinicopathological features of triple-negative breast cancer in Taiwanese women,” International Journal of Clinical Oncology, vol. 15, no. 5, pp. 500–505, 2011.

[5] B. L. Pierce, R. Ballard-Barbash, L. Bernstein et al., “Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3437–3444, 2009.

[6] A. Mantovani, F. Marchesi, C. Porta, A. Sica, and P. Allavena, “Inflammation and cancer: breast cancer as a prototype,” Breast, vol. 16, supplement 2, pp. 27–33, 2007.

[7] A. Nicolini, A. Carpi, and G. Rossi, “Cytokines in breast cancer,” Cytokine & Growth Factor Reviews, vol. 17, no. 5, pp. 325–337, 2006.

[8] F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001.

[9] L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.

[10] A. Ben-Baruch, “The multifaceted roles of chemokines in malignancy,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 357–371, 2006.

[11] T. Boon and B. van den Eynde, “Tumour immunology,” Current Opinion in Immunology, vol. 15, no. 2, pp. 129–130, 2003.

[12] J. Wilson and F. Balkwill, “The role of cytokines in the epithelial cancer microenvironment,” Seminars in Cancer Biology, vol. 12, no. 2, pp. 113–120, 2002.

[13] C. H. Hsing, H. C. Cheng, Y. H. Hsu et al., “Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome,” Clinical Cancer Research, vol. 18, no. 3, pp. 713–725, 2012.

[14] W. E. Naugler and M. Karin, “The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer,” Trends in Molecular Medicine, vol. 14, no. 3, pp. 109–119, 2008.

[15] J. Massague, “TGFbeta in cancer,” Cell, vol. 134, no. 2, pp. 215–230, 2008.

[16] P. Romagnani, L. Lasagni, F. Annunziato, M. Serio, and S. Romagnani, “CXCR chemokines: the regulatory link between inflammation and angiogenesis,” Trends in Immunology, vol. 25, no. 4, pp. 201–209, 2004.

[17] C. Chavey, F. Bibeau, S. Bourgou-Bourgade et al., “Oestrogen receptor negative breast cancers exhibit high cytokine content,” Breast Cancer Research, vol. 9, no. 1, article R15, 2007.

[18] S. U. Woo, J. W. Bae, J. H. Yang, J. H. Kim, S. J. Nam, and Y. K. Shin, “Overexpression of interleukin-10 in sentinel lymph node with breast cancer,” Annals of Surgical Oncology, vol. 14, no. 11, pp. 3268–3273, 2007.

[19] N. J. Sullivan, A. K. Sasser, A. E. Axel et al., “Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells,” Oncogene, vol. 28, no. 33, pp. 2940–2947, 2009.

[20] A. Purohit, S. P. Newman, and M. J. Reed, “The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer,” Breast Cancer Research, vol. 4, no. 2, pp. 65–69, 2002.

[21] M. E. E. SABBIONI, H. P. SIEGRIEST, M. BACCHI et al., “Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment,” Breast Cancer Research and Treatment, vol. 59, no. 3, pp. 279–287, 2000.

[22] C. H. Hsing, H. H. Li, Y. H. Hsu et al., “The distribution of interleukin-19 in healthy and neoplastic tissue,” Cytokine, vol. 44, no. 2, pp. 221–228, 2008.

[23] S. Commins, J. W. Steinke, and L. Borish, “The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29,” Journal of Allergy and Clinical Immunology, vol. 121, no. 5, pp. 1108–1111, 2008.

[24] G. Gallagher, “Interleukin-19: multiple roles in immune regulation and disease,” Cytokine and Growth Factor Reviews, vol. 21, no. 5, pp. 345–352, 2010.

[25] K. Wolk, S. Kunz, K. Asadullah, and R. Sabat, “Cutting edge: immune cells as sources and targets of the IL-10 family members?” Journal of Immunology, vol. 168, no. 11, pp. 5397–5402, 2002.

[26] W. Ouyang, S. Rutz, N. K. Crellin et al., “Regulation and functions of the IL-10 family of cytokines in inflammation and disease,” Annual Review of Immunology, vol. 29, pp. 71–109, 2011.

[27] H. Fickenscher, S. Hör, H. Käpers, A. Knappe, S. Wittmann, and H. Sticht, “The interleukin-10 family of cytokines,” Trends in Immunology, vol. 23, no. 2, pp. 89–96, 2002.

[28] L. Dumoutier, C. Leemans, D. Lejeune, S. V. Kotenko, and J. C. Renaud, “Cutting edge: STAT activation by IL-19, IL-20, IL-26, IL-28B and IL-29,” Journal of Immunology, vol. 167, no. 7, pp. 3545–3549, 2001.

[29] A. Zdanov, “Structural features of the interleukin-10 family of cytokines,” Current Pharmaceutical Design, vol. 10, no. 31, pp. 3873–3884, 2004.

[30] C. Chang, E. Magracheva, S. Kozlov et al., “Crystal structure of interleukin-19 defines a new subfamily of helical cytokines,” Journal of Biological Chemistry, vol. 278, no. 5, pp. 3308–3313, 2003.

[31] P. Conti, D. Kempuraj, S. Frydas et al., “IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26,” Immunology Letters, vol. 88, no. 3, pp. 171–174, 2003.

[32] S. Pestka, C. D. Krause, S. Kozlov et al., “Interleukin-10 and related cytokines and receptors,” Annual Review of Immunology, vol. 22, pp. 929–979, 2004.

[33] J. A. Langer, E. C. Cutrone, and S. Kotenko, “The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions,” Cytokine and Growth Factor Reviews, vol. 15, no. 1, pp. 33–48, 2004.
[34] S. V. Kotenko, “The family of IL-10-related cytokines and their receptors: related, but to what extent?” Cytokine and Growth Factor Reviews, vol. 13, no. 3, pp. 223–240, 2002.

[35] G. Gallagher, H. Dickensheets, J. Eskdale et al., “Cloning, expression and initial characterisation of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10),” Genes and Immunity, vol. 1, no. 7, pp. 442–450, 2000.

[36] C. H. Hsing, M. Y. Hsieh, W. Y. Chen, E. Cheung So, B. C. Cheng, and M. S. Chang, “Induction of interleukin-19 and interleukin-22 after cardiac surgery with cardiopulmonary bypass,” Annals of Thoracic Surgery, vol. 81, no. 6, pp. 2196–2201, 2006.

[37] Y. C. Liao, W. G. Liang, F. W. Chen, J. H. Hsu, J. J. Yang, and M. S. Chang, “IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α,” Journal of Immunology, vol. 169, no. 8, pp. 4288–4297, 2002.

[38] S. C. Liao, Y. C. Cheng, Y. C. Wang et al., “IL-19 induced Th2 cytokines and was up-regulated in asthma patients,” Journal of Immunology, vol. 173, no. 11, pp. 6712–6718, 2004.

[39] S. Pletsnev, E. Magracheva, S. Kozlov et al., “Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20,” Biochemistry, vol. 42, no. 43, pp. 12617–12624, 2003.

[40] D. Preimel and H. Sticht, “Molecular modeling of the interleukin-19 receptor complex. Novel aspects of receptor recognition in the interleukin-10 cytokine family,” Journal of Molecular Modeling, vol. 10, no. 4, pp. 290–296, 2004.

[41] J. Parrish-Novak, W. Xu, T. Brendler et al., “Interleukins 19, 20, and 24 signal through two distinct receptor complexes: differences in receptor- ligand interactions mediate unique biological functions,” Journal of Biological Chemistry, vol. 277, no. 49, pp. 47517–47523, 2002.

[42] R. Menon, L. Ismail, D. Ismail, M. Merialiad, S. J. Lombardi, and S. J. Fortunato, “Human fetal membrane expression of IL-19 and IL-20 and its differential effect on inflammatory cytokine production,” Journal of Maternal-Fetal & Neonatal Medicine, vol. 19, no. 4, pp. 209–214, 2006.

[43] Y. T. Azuma, Y. Matsu, M. Kuwamura et al., “Interleukin-19 protects mice from innate-mediated colonic inflammation,” Inflammatory Bowel Diseases, vol. 16, no. 6, pp. 1017–1028, 2010.

[44] A. A. Cuneo, D. Herrick, and M. V. Autieri, “IL-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability,” Journal of Molecular and Cellular Cardiology, vol. 49, no. 4, pp. 647–654, 2010.

[45] C. H. Yeh, B. C. Cheng, C. C. Hsu et al., “Induced interleukin-19 contributes to cell-mediated immunosuppression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass,” Annals of Thoracic Surgery, vol. 92, no. 4, pp. 1252–1259, 2011.

[46] C. H. Hsing, C. J. Chiu, L. Y. Chang, C. C. Hsu, and M. S. Chang, “IL-19 is involved in the pathogenesis of endotoxic shock,” Shock, vol. 29, no. 1, pp. 7–15, 2008.

[47] C. H. Hsing, C. C. Hsu, W. Y. Chen, L. Y. Chang, J. C. Hwang, and M. S. Chang, “Expression of IL-19 correlates with Th2 cytokines in uroemic patients,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp. 2230–2238, 2007.

[48] H. H. Li, Y. C. Lin, P. J. Chen et al., “Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis,” British Journal of Dermatology, vol. 153, no. 3, pp. 591–595, 2005.

[49] N. Sakurai, T. Kuroiwa, H. Ikeuchi et al., “Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation,” Rheumatology, vol. 47, no. 6, pp. 815–820, 2008.

[50] K. Gabunia, S. P. Ellison, H. Singh et al., “Interleukin-19 (IL-19) induces heme oxygenase-1 (HO-1) expression and decreases reactive oxygen species in human vascular smooth muscle cells,” Journal of Biological Chemistry, vol. 287, no. 4, pp. 2477–2484, 2012.

[51] L. Huang, H. C. Cheng, R. Isom, C. S. Chen, R. A. Levine, and B. U. Pauli, “Protein kinase Cζ mediates polymeric fibronectin assembly on the surface of blood-borne rat breast cancer cells to promote pulmonary metastasis,” Journal of Biological Chemistry, vol. 283, no. 12, pp. 7616–7627, 2008.

[52] N. Chaudarya and R. P. Hill, “Hypoxia and metastasis in breast cancer,” Breast Disease, vol. 26, no. 1, pp. 55–64, 2006.

[53] D. Generali, A. Berruti, M. P. Brizzi et al., “Hypoxia-inducible factor-κα expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer,” Clinical Cancer Research, vol. 12, no. 15, pp. 4562–4568, 2006.

[54] Y. M. Li, Y. Pan, Y. Wei et al., “Uregulation of CXCR4 is essential for HER2-mediated tumor metastasis,” Cancer Cell, vol. 6, no. 5, pp. 459–469, 2004.

[55] R. Paduch, A. Walter-Croneck, B. Zdzisinska, A. Szuster-Ciesielska, and M. Kandefer-Szerszen, “Role of reactive oxygen species (ROS), metalloproteinase-2 (MMP-2) and interleukin-6 (IL-6) in direct interactions between tumour cell spheroids and endothelial cell monolayer,” Cell Biology International, vol. 29, no. 7, pp. 497–505, 2005.

[56] R. C. Johnson, D. Zhu, H. G. Augustin-Voss, and B. U. Pauli, “Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung- metastatic rat breast and prostate carcinoma cells,” Journal of Cell Biology, vol. 121, no. 6, pp. 1423–1432, 1993.

[57] M. Stein, S. Keshav, N. Harris, and S. Gordon, “Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation,” Journal of Experimental Medicine, vol. 176, no. 1, pp. 287–292, 1992.

[58] J. E. Maglione, D. Moghanaki, L. J. Young et al., “Transgenic Polyoma middle-T mice model premalignant mammary disease,” Cancer Research, vol. 61, no. 22, pp. 8298–8305, 2001.

[59] H. Maeda, H. Kuwahara, Y. Ichimura, M. Ohsuki, S. Kurakata, and A. Shiraishi, “TGF-β enhances macrophage ability to produce IL-10 in normal and tumor- bearing mice,” Journal of Immunology, vol. 155, no. 10, pp. 4926–4932, 1995.

[60] F. Balkwill, K. A. Charles, and A. Mantovani, “Smoldering and polarized inflammation in the initiation and promotion of malignant disease,” Cancer Cell, vol. 7, no. 3, pp. 211–217, 2005.

[61] K. Watanabe, P. J. Jose, and S. M. Rankin, “Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages,” Journal of Immunology, vol. 168, no. 4, pp. 1911–1918, 2002.

[62] S. K. Bunt, L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg, “Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression,” Cancer Research, vol. 67, no. 20, pp. 10019–10026, 2007.

[63] G. Gallagher, J. Eskdale, W. Jordan et al., “Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses,” International Immunopharmacology, vol. 4, no. 5, pp. 615–626, 2004.

[64] J. A. Lederer, M. L. Rodrick, and J. A. Mannick, “The effects of injury on the adaptive immune response,” Shock, vol. 11, no. 3, pp. 153–159, 1999.
[65] S. T. O'Sullivan, J. A. Lederer, A. F. Horgan et al., “Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection,” *Annals of Surgery*, vol. 222, no. 4, pp. 482–492, 1995.
